Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Gains from Investment Securities (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Gains from Investment Securities for 10 consecutive years, with $5000.0 as the latest value for Q1 2026.

  • For Q1 2026, Gains from Investment Securities changed N/A year-over-year to $5000.0; the TTM value through Mar 2026 reached $1.6 million, up 2541.76%, while the annual FY2025 figure was $1.7 million, 3703.12% up from the prior year.
  • Gains from Investment Securities hit $5000.0 in Q1 2026 for Crescent Biopharma, down from $1.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8.8 million in Q2 2023 and bottomed at -$90720.0 in Q4 2023.
  • Average Gains from Investment Securities over 5 years is $1.9 million, with a median of $584200.0 recorded in 2022.
  • On a YoY basis, Gains from Investment Securities climbed as much as 2415.33% in 2024 and fell as far as 93.34% in 2024.
  • Crescent Biopharma's Gains from Investment Securities stood at $584200.0 in 2022, then plummeted by 115.53% to -$90720.0 in 2023, then soared by 743.96% to $584200.0 in 2024, then surged by 179.01% to $1.6 million in 2025, then plummeted by 99.69% to $5000.0 in 2026.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $5000.0, $1.6 million, and $584200.0 for Q1 2026, Q2 2025, and Q2 2024 respectively.